Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Rapid correction of low vitamin D status in nursing home residents 3. 2008 Exclusive Survey—Earnings: Good news for primary care income 4. Medicare pay-for-reporting effort draws fire from frustrated doctors 5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment
Top Ten Searches
rheumatoid arthritis lupus polymyalgia sjogrens fibromyalgia amyloidosis vasculitis urate raynauds myositisYour Article Summary
See Latest ArticlesEffect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy
Seminars in Arthritis and Rheumatism, 06/30/09
Barnabe C et al. - Anti-TNFα therapies are reported to have beneficial effects on bone density and bone turnover markers. However, retrieved studies in this review were heterogeneous with regards to patients studied, underlying risks for osteoporosis, and supplemental therapy, which may limit the findings of the true effect of anti-TNFα therapy on bone.
Methods- Review of current literature reporting on:
- Effect of anti-TNFα on bone density as measured by DEXA at the lumbar spine and hip
- Effect on markers of bone turnover and resorption, in pts using anti-TNFα for rheumatic disease indications
- PubMed search, as well as manual search of related articles and references of articles retrieved
- Studies pertaining to the effect of anti-TNFα therapy on BMD and bone turnover markers were included
- In RA, 4 studies (238 pts) showed a stabilization or increase of BMD at the spine or hip with only 1 negative study in 48 pts
- In spondyloarthopathies, 3 studies (75 pts) all demonstrated an increase in BMD at the lumbar spine and at the hip
- Changes in markers of bone formation and bone resorption were heterogeneous but in general represented a modest increase in formation and decline in resorption
Today in Rheumatoid Arthritis...keeping you current
Receive free subspecialty "5-minute updates" via email
Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study
Arthritis Care and Research , 11/03/09
Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor [alpha] therapies: Does the risk change with the time since start of treatment?
Arthritis & Rheumatism, 11/05/09
Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up
Scandinavian Journal of Rheumatology , 09/28/09
Today in Spondylarthropathies...keeping you current
Receive free subspecialty "5-minute updates" via email
Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in one rheumatological center: two years drug survival
Rheumatology International, 10/14/09
Erythrocyte sedimentation rate, CRP level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis
Arthritis Care and Research , 11/02/09
Recreational Exercise in Rheumatic Diseases
International Journal of Sports Medicine, 10/30/09
Sponsor
Article Search
Sponsor